SEC Form 4 · accession 0001209191-15-004402
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L. Hoerter
Officer — See Remarks
Period of report
Jan 13, 2015
Accepted (ET)
Jan 15, 2015 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 13, 2015 | M | 10,000 | $11.02 | A | 10,000 | D | |
| Common Stock | Jan 13, 2015 | S | 10,000 | $62.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $11.02 | Jan 13, 2015 | M | 10,000 | D | — | Aug 29, 2021 | Common Stock | 10,000 | 66,206 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.
- F2The option is immediately exercisable as to both vested and unvested shares. The option vested as to 25% of the shares on August 29, 2012 and the remainder have and will continue to vest in substantially equal installments over the 36 months immediately following such date. To the extent the reporting person exercises the option as to unvested shares, the reporting person will receive restricted shares that will vest in accordance with the vesting schedule for the option.
Remarks
Senior Vice President of Commercial Operations